Tomas Ganz
Pulmonary Disease · Los Angeles, CANPI 1083639264
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $74,753 of the $108,376 with a category attached, or 69.0%. 16 manufacturers reported payments, led by Vifor (international) Ltd. at 34.5% of the total. 2025 is the largest year on record at $32,466, 3.0 times the $10,772 reported in 2019. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $2580.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor (international) Ltd.$37K
- Pharmacosmos Therapeutics Inc.$27K
- American Regent$12K
- Akebia Therapeutics Inc$8K
- GSK$7K
- Rockwell Medical, Inc.$4K
- plus $13K from 10 others
Across 4 payments — averaging $68,817 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$225K
- Ionis Pharmaceuticals, Inc.$50K
What the payments were for
- Consulting fees$74,75369%
- Speaking & faculty fees$4,2254%
- Travel & lodging$28,47326%
- Food & beverage$9251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor (international) Ltd. | 6 | $37,343 |
| Pharmacosmos Therapeutics Inc. | 9 | $26,541 |
| American Regent | 3 | $12,002 |
| Akebia Therapeutics Inc | 6 | $8,132 |
| GSK | 2 | $6,900 |
| Rockwell Medical, Inc. | 2 | $4,300 |
| Incyte Corporation | 3 | $3,575 |
| AstraZeneca | 1 | $3,222 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $1,898 |
| Novartis | 1 | $1,446 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,208 |
| CSL Behring | 1 | $723 |
| Alnylam Pharmaceuticals Inc. | 1 | $615 |
| Agios Pharmaceuticals, Inc. | 1 | $300 |
| Apo-pharma Inc. | 1 | $125 |
| Regeneron | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$26,513
- INJECTAFER$11,971
- AURYXIA$4,473
- TRIFERIC$4,300
- JAKAFI$1,446
- FERRIPROX$125
How this compares
$108,376 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.